This inventor holds 5 USPTO granted patents. Top assignees: Probiodrug Ag, Other. Active years: 2003-2012.
Location History:
- Halle/Saale, DE (2003)
- Halle, DE (2006)
- Alfter, DE (2008 - 2012)
Company Filing History:
4 out of 73 
1 out of 834,411 Years Active: 2003-2012
Title: Susanne Kruber: Innovator in Neuropsychiatric Treatments
Introduction
Susanne Kruber is a prominent inventor based in Alfter, Germany. She has made significant contributions to the field of neuropsychiatric treatments, holding a total of five patents. Her work focuses on innovative methods for treating various mental health conditions, including schizophrenia and anxiety.
Latest Patents
Among her latest patents are two notable inventions related to dipeptidyl peptidase IV (DP IV) inhibitors. The first patent outlines a method for therapeutically treating animals, including humans, for psychosomatic, depressive, and neuropsychiatric diseases. This includes conditions such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm, and chronic pain. The administration of a suitable DP IV inhibitor reduces the activity of the enzyme DP IV in the brain, leading to a decrease in the degradation of neuropeptide Y (NPY). This results in enhanced stability of NPY, which facilitates various neurological effects, including antidepressive and anxiolytic properties.
The second patent similarly discloses a method for treating anxiety through the use of DP IV inhibitors. The therapeutic approach aims to prolong the activity of NPY, thereby providing relief from anxiety and other related conditions.
Career Highlights
Throughout her career, Susanne Kruber has worked with notable companies, including Probiodrug AG. Her innovative research has positioned her as a key figure in the development of new treatments for mental health disorders.
Collaborations
She has collaborated with esteemed colleagues such as Hans-Ulrich Demuth and Ants Kask, contributing to the advancement of her research and inventions.
Conclusion
Susanne Kruber's work in developing DP IV inhibitors represents a significant advancement in the treatment of neuropsychiatric diseases. Her contributions continue to impact the field positively, offering hope for improved therapeutic options for patients.